ES2912267T3 - Métodos de tratamiento de enfermedades asociadas a S. aureus - Google Patents
Métodos de tratamiento de enfermedades asociadas a S. aureus Download PDFInfo
- Publication number
- ES2912267T3 ES2912267T3 ES13853844T ES13853844T ES2912267T3 ES 2912267 T3 ES2912267 T3 ES 2912267T3 ES 13853844 T ES13853844 T ES 13853844T ES 13853844 T ES13853844 T ES 13853844T ES 2912267 T3 ES2912267 T3 ES 2912267T3
- Authority
- ES
- Spain
- Prior art keywords
- antibody
- aureus
- amino acid
- seq
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Gram-positive bacteria
- C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723128P | 2012-11-06 | 2012-11-06 | |
| PCT/US2013/068385 WO2014074470A1 (en) | 2012-11-06 | 2013-11-05 | Methods of treating s. aureus-associated diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2912267T3 true ES2912267T3 (es) | 2022-05-25 |
Family
ID=50685101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13853844T Active ES2912267T3 (es) | 2012-11-06 | 2013-11-05 | Métodos de tratamiento de enfermedades asociadas a S. aureus |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9845348B2 (enExample) |
| EP (1) | EP2928490B1 (enExample) |
| JP (2) | JP6506172B2 (enExample) |
| KR (3) | KR20210083389A (enExample) |
| CN (2) | CN112316135A (enExample) |
| AU (2) | AU2013341421A1 (enExample) |
| BR (1) | BR112015010126B1 (enExample) |
| CA (1) | CA2890385C (enExample) |
| ES (1) | ES2912267T3 (enExample) |
| MX (1) | MX367082B (enExample) |
| RU (1) | RU2661406C2 (enExample) |
| SG (2) | SG11201503231YA (enExample) |
| WO (1) | WO2014074470A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2014100111A (ru) | 2011-06-10 | 2015-07-20 | МЕДИММЬЮН, ЭлЭлСи | МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Psl Pseudomonas, И ПУТИ ИХ ПРИМЕНЕНИЯ |
| HRP20201370T1 (hr) | 2011-11-07 | 2020-11-27 | Medimmune Limited | Kombinacijske terapije koje koriste anti-pseudomonas psl i pcrv vezujuće molekule |
| BR112015010125A2 (pt) * | 2012-11-06 | 2017-08-22 | Medimmune Llc | Anticorpo isolado ou seu fragmento de ligação, composição, ácido nucleico isolado, métodos de determinação da presença de s. aureus em uma amostra de teste, de tratamento de uma infecção por s. aureus em um paciente, de prevenção ou redução da gravidade de sepsia associada a s. aureus em um paciente, de atraso do início de sepsia associada a infecção por s. aureus em um paciente, de prevenção do início de sepsia associada a infecção por s. aureus em um paciente, de redução de carga bacteriana de s. aureus na corrente sanguínea ou coração em um paciente, e de redução da aglutinação bacteriana de s. aureus e/ou formação de lesões tromboembólicas em um paciente |
| KR20210083389A (ko) * | 2012-11-06 | 2021-07-06 | 메디뮨 엘엘씨 | 에스.아우레우스 연관 질병의 치료 방법 |
| TWI719938B (zh) | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
| TWI781130B (zh) | 2017-01-03 | 2022-10-21 | 美商再生元醫藥公司 | 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體 |
| JP7525471B2 (ja) | 2018-07-24 | 2024-07-30 | メディミューン，エルエルシー | Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）クランピング因子Ａ（ＣｌｆＡ）に対する抗体 |
| TWI895248B (zh) | 2018-10-09 | 2025-09-01 | 美商麥迪紐有限責任公司 | 針對金黃色葡萄球菌白血球毒素的抗體 |
| BR112021006622A2 (pt) | 2018-10-09 | 2021-07-20 | Medimmune, Llc | combinações de anticorpos anti-staphylococcus aureus |
| CN113811544A (zh) | 2019-03-13 | 2021-12-17 | 免疫医疗有限责任公司 | 减少定殖患者中的金黄色葡萄球菌感染 |
| CN112538112B (zh) * | 2019-09-20 | 2023-10-27 | 迈威(上海)生物科技股份有限公司 | 抗α-溶血素的抗体及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080131457A1 (en) * | 2006-06-12 | 2008-06-05 | Nabi Biopharmaceuticals | Use of alpha-toxin for treating and preventing staphylococcus infections |
| JP5658564B2 (ja) * | 2007-08-31 | 2015-01-28 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物 |
| EP2453881A2 (en) * | 2009-07-16 | 2012-05-23 | Georgia Health Sciences University Research Institute, Inc. | Porous-wall hollow glass microspheres as carriers for biomolecules |
| EP2284193A1 (en) * | 2009-08-10 | 2011-02-16 | Kenta Biotech AG | Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation |
| AU2012214677B2 (en) * | 2011-02-08 | 2016-11-10 | Abvacc, Inc. | Immunogenic composition comprising alpha-hemolysin oligopeptides |
| PT2673373T (pt) * | 2011-02-08 | 2018-12-05 | Medimmune Llc | Anticorpos que ligam especificamente a toxina alfa de staphylococcus aureus e métodos de utilização |
| BR112015010125A2 (pt) | 2012-11-06 | 2017-08-22 | Medimmune Llc | Anticorpo isolado ou seu fragmento de ligação, composição, ácido nucleico isolado, métodos de determinação da presença de s. aureus em uma amostra de teste, de tratamento de uma infecção por s. aureus em um paciente, de prevenção ou redução da gravidade de sepsia associada a s. aureus em um paciente, de atraso do início de sepsia associada a infecção por s. aureus em um paciente, de prevenção do início de sepsia associada a infecção por s. aureus em um paciente, de redução de carga bacteriana de s. aureus na corrente sanguínea ou coração em um paciente, e de redução da aglutinação bacteriana de s. aureus e/ou formação de lesões tromboembólicas em um paciente |
| KR20210083389A (ko) * | 2012-11-06 | 2021-07-06 | 메디뮨 엘엘씨 | 에스.아우레우스 연관 질병의 치료 방법 |
| TWI719938B (zh) | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
| WO2017075188A2 (en) | 2015-10-30 | 2017-05-04 | Medimmune, Llc | Methods of using anti-alpha toxin antibody |
-
2013
- 2013-11-05 KR KR1020217020104A patent/KR20210083389A/ko not_active Ceased
- 2013-11-05 EP EP13853844.2A patent/EP2928490B1/en active Active
- 2013-11-05 BR BR112015010126-7A patent/BR112015010126B1/pt active IP Right Grant
- 2013-11-05 CA CA2890385A patent/CA2890385C/en active Active
- 2013-11-05 SG SG11201503231YA patent/SG11201503231YA/en unknown
- 2013-11-05 RU RU2015121617A patent/RU2661406C2/ru active
- 2013-11-05 KR KR1020207024078A patent/KR102272744B1/ko active Active
- 2013-11-05 CN CN202011217117.7A patent/CN112316135A/zh active Pending
- 2013-11-05 JP JP2015540852A patent/JP6506172B2/ja active Active
- 2013-11-05 WO PCT/US2013/068385 patent/WO2014074470A1/en not_active Ceased
- 2013-11-05 MX MX2015005481A patent/MX367082B/es active IP Right Grant
- 2013-11-05 SG SG10201703677VA patent/SG10201703677VA/en unknown
- 2013-11-05 KR KR1020157011460A patent/KR20150092738A/ko not_active Ceased
- 2013-11-05 CN CN201380057604.3A patent/CN104780934A/zh active Pending
- 2013-11-05 US US14/440,749 patent/US9845348B2/en active Active
- 2013-11-05 ES ES13853844T patent/ES2912267T3/es active Active
- 2013-11-05 AU AU2013341421A patent/AU2013341421A1/en not_active Abandoned
-
2017
- 2017-12-18 US US15/845,701 patent/US10457724B2/en active Active
-
2018
- 2018-09-28 AU AU2018236849A patent/AU2018236849B2/en active Active
-
2019
- 2019-03-28 JP JP2019063358A patent/JP6926138B2/ja active Active
- 2019-10-11 US US16/599,595 patent/US10759849B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2912267T3 (es) | Métodos de tratamiento de enfermedades asociadas a S. aureus | |
| JP6694269B2 (ja) | Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）表面決定基に対する抗体 | |
| US20150044168A1 (en) | Treatment of Multiple Sclerosis With Anti-CD19 Antibody | |
| JP2022512647A (ja) | 抗黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）抗体の組み合わせ | |
| US12570744B2 (en) | Bispecific PD-1 and TIGIT binding proteins and uses thereof | |
| US20240109961A1 (en) | Treatment of chronic prurigo | |
| HK1215173B (en) | Methods of treating s. aureus-associated diseases | |
| US20240392005A1 (en) | Pd-1/tigit binding proteins for cancer treatment | |
| TW202511292A (zh) | 用於治療ＮＳＣＬＣ及ｃＨＬ之ＰＤ－１／ＴＩＭ－３結合蛋白 | |
| WO2025250726A1 (en) | Anti-kit antibody dosing and methods | |
| CN117120089A (zh) | 慢性痒疹的治疗 |